HDL Function Dietary Supplement Safety and QOL

Inclusion Criteria: * Men: Total HDL of equal to or less than 38 mg / dL in men AND a low HDL-P of less than or equal to 7200 by Spectracell LPP Plus. * Women: Total HDL equal to or less than 45 mg/dl in women, AND a low HDL-P of less than or equal to 7200 by Spectracell LPP Plus. * Willingness to maintain current lifestyle (diet and exercise) practices * Willingness to eat fish no more than twice per week and keep intake stable throughout the study * Willingness to give written informed consent to participate in the study * Willingness to follow lifestyle instructions for 24 hours prior to the study visit. * No known food allergy or intolerance to the ingredients in the study product (fish, shellfish) * Not currently taking (washout of at least 30 days required) any other supplements that would interfere with the study results * Not currently taking (washout of at least 30 days required) any other supplements designed to support HDL. Exclusion Criteria: * Use of medications classified as narcotics 30 days prior to Screening and for the duration of the study. * Use of an investigational drug or participation in an investigational study within 30 days prior to Day 1 and for the duration of the study. * Current use (at least 30 days wash-out required) of any lipid lowering medication which, in the view of the PI, may interfere with the results. * Known allergy or hypersensitivity to study product. * No initiation of a new or change of an existing exercise regimen within 15 days prior to Day 1 and for the duration of the study. * No initiation of a new or change of an existing food plan 30 days prior to Day 1 and for the duration of the study. * No current involvement or within 30 days of Day 1 of a significant diet or weight loss program such as Atkin's or other Low-Carb diet programs, very low calorie liquid diet programs (such as Optifast, Medifast and/or HMR) or any diet that has led to a weight loss of 5% of body weight over a period of 10 weeks. * No serious, unstable illnesses including cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrine, neurologic, immunologic, or hematologic disease. * Known infection with Human Immunodeficiency Virus (HIV), Tuberculosis or Hepatitis B or C. * Subjects with a current diagnosis or personal history of: * Previous myocardial infarction within 5 years, Unstable angina, Previous stroke or transient ischemic attack (TIA) within 5 years, Uncompensated congestive heart failure, Previous percutaneous transluminal coronary angioplasty (PCTA) or stent within 5 years, Previous coronary artery bypass grafts (CABG) within 5 years * Type 1 diabetes mellitus * Any significant liver or kidney disease such as cirrhosis or non-alcoholic fatty liver disease, glomerulonephritis, and/or undergoing dialysis treatment. Cr over 2.5 mg/dL. * Any malignancy (with the exception of basal or squamous cell carcinoma of the skin if adequately treated and no recurrence for \>5 years). * Any serious mental illness including depression, manic episodes, post-traumatic disorder, obsessive-compulsive disorder, personality disorders, history of attempted suicide or violence within 12 months prior to Screening and for the duration of the study. * Any personal history of bipolar disorders, schizophrenia or psychotic behaviors. * Personal history of seizure disorder other than a single childhood febrile seizure that fully resolved. * Known presence of raised intraocular pressure or history of narrow angle glaucoma. * A major medical or surgical event requiring hospitalization within the preceding 3 months * The presence of any disease which influences digestion and absorption of nutrients * History of any bariatric surgery procedure * Consumption of alcohol the evening prior to any study visit * Use of drugs of abuse (such as marijuana, cocaine, phencyclidine \[PCP\] and methamphetamine) within 12 months prior to Screening and for the duration of the study. * History of alcohol abuse or a diagnosis of alcoholism within 12 months prior to Screening and for the duration of the study. * Inability to comply with study and/or follow-up visits. * Any other concurrent condition which, in the opinion of the Investigator, would preclude participation in this study or interfere with compliance. * Pregnancy * Females of child bearing age not on an accepted contraception control method